Universal Community Nucleic Acid Testing for COVID-19 in Hong Kong Reveals Insights into Transmission Dynamics

Background: Testing of an entire community has been used as an approach to control COVID-19. In Hong Kong, a universal community testing programme (UCTP) was implemented at the fadeout phase of a community epidemic in July to September 2020, to determine the prevalence of unrecognised cases and limit any remaining transmission chains. We described the utility of the UCTP in finding unrecognised cases, and analysed data from the UCTP and other sources to characterise transmission dynamics.Methods: We described the characteristics of people participating in the UCTP, and compared the clinical and epidemiological characteristics of COVID-19 cases detected by the UCTP versus those detected by clinical diagnosis and public health surveillance. We developed a Bayesian model to estimate the age-specific incidence of infection and the proportion of cases detected by clinical diagnosis and public health surveillance.Findings: 1.77 million people, 24% of the Hong Kong population, participated in the UCTP from 1 to 14 September 2020. The UCTP identified 32 new infections (1.8 per 100,000 samples tested), consisting of 29% of all local cases reported during the two-week UCTP period. Compared with the existing clinical diagnosis and public health surveillance, the UCTP detected a higher proportion of sporadic cases (62% versus 27%, p <0.01) and identified 6 (out of 18) additional transmission chains during that period. We estimated that 27% (95% credible interval: 22%, 34%) of all infections were detected by the existing clinical diagnosis and public health surveillance in the third wave.Interpretation: We reported empirical evidence of the utility of population-wide COVID-19 testing in detecting unrecognised infections and transmission chains. Around three quarters of infections have not been identified through existing surveillance approaches including contact tracing.Funding Statement: This project was supported by the Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong Special Administrative Region (grant no. COVID190118).Declaration of Interests: BJC consults for Roche, Sanofi Pasteur, GSK and Moderna. The authors report no other potential conflicts of interest.Ethics Approval Statement: Our project was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB).